SOLICITATION NOTICE
B -- Array-CGH on paraffin-embedded formali-fixed (FFPE) melanoma tumor samples
- Notice Date
- 9/7/2010
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100235-TG
- Archive Date
- 9/30/2010
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6068, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG), Genetic Epidemiology Branch (GEB) plans to procure on a sole source basis DNA methylation, mi RNA and gene expression analyses from Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton Oxford OX5 1PF UK. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 541380 and the business size standard is $12.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Twelve months from Date of award DNA copy number changes are among the most common mechanisms that can lead to altered expression and function of genes residing within the affected region of the genome. Identifying regions with copy number aberrations and relate them to UV exposures, pigmentation phenotypes, and tumor characteristics will improve our understanding of the molecular basis and classification of melanoma. Over the past decade, the microarray-based comparative genomic hybridization (array-CGH) technology has been developed and used as a powerful tool enabling the genome-wide detection of DNA copy-number aberrations in various types of cancers. Genomic copy number profiles can also distinguish distinct tumor subtypes. For example, copy number patterns classified breast tumors into specific subtypes that correspond to those previously defined by mRNA expression profiling (Bergamaschi A, 2006). Recently, array-CGH has been successfully applied to amplified DNA from FFPE tissue sections, allowing the possibility of profiling a large number of tumors and classifing them into subtypes. The contractor shall classify 100 melanomas according to their genetic alteration profiles in primary melanomas collected from the residual tissue repository (RTR) of the Surveillance, Epidemiology, and End Results (SEER) program. Specifically, the contractor shall perform array-CGH analysis using DNA extracted from archival FFPE primary melanomas collected in the LA SEER RTR. The NCI will then correlate the molecular changes with age at diagnosis, ethnicity, sites of origin, important tumor features, and survival. Results from this study will be critical to evaluate the feasibility of classifying primary melanomas using archival tissues. Oxford Gene Technology (OGT) was the first company to be named as a High-Throughput Certified Service Provider (HT CSP) for Agilent microarrays. This new level of the Agilent certification provides official validation of OGT's use of Agilent microarrays in a high-throughput environment and reflects OGT's status as the supplier of choice for large-scale outsourced microarray studies. Profiling archival FFPE tissues, which are the only tumor tissue resources available for large tumor collections, has been challenging. Due to formalin fixation, DNA undergoes extensive degradation and therefore is poor substrate for amplification and quantification, particularly with the use of less ideal fixation agents and long storage time. OGT's use of Agilent allows for the use of the only available assay that provides a specifically designed and validated CGH protocol for FFPE tissues. The certificate was awarded following rigorous assessment of the high-quality experimental data routinely generated by OGT's unique high-throughput analysis service. NCI has been using OGT's aCGH service for other melanoma related projects and it is critical to use the same experimental protocol for direct comparisons. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received at the NCI Office of Acquisitions on or before 11:00 AM EST on September 15, 2010. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Terry Galloway, Contract Specialist at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100235-TG on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100235-TG/listing.html)
- Record
- SN02271132-W 20100909/100908063528-c76493be1ca61062a0a7bf5daafdcd7a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |